Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

Healthcare Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.


TSXV:NRX - Post by User

NurExone Biologic Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by PressReleaseon Apr 25, 2024 8:35am
49 Views
Post# 36006685

New Press Release - NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility

New Press Release - NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
TORONTO and HAIFA, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company is pleased to announce that its common shares are now quoted for trading on the OTCQB® Venture Market (the "OTCQB")...read article.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities